Skip to the page

Data / Drug companies / Optimus Drugs Private Limited

Optimus Drugs Private Limited: 41 products in the FDA NDC directory, labeler code 59285

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Optimus Drugs Private Limited (labeler code 59285) lists 41 products in the FDA National Drug Code Directory. By type: 41 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on March 27, 2025.

The request: Watch Optimus Drugs Private Limited (FDA labeler code 59285): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
59285
Products in commercial distribution
41
Packages
41
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Controlled substance products
Schedule V 3
Started marketing in the last 12 months
0
Earliest marketing start
April 30, 2014
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Bulk ingredients41100%

Products by type

TypeProductsShare
Bulk ingredients41100%

Dosage forms

Dosage formProductsShare
Powder41100%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Empagliflozin59285-060PowderBulk ingredientsMarch 27, 2025
Cariprazine hydrochloride59285-063PowderBulk ingredientsNovember 4, 2024
Linezolid (form-iii)59285-056PowderBulk ingredientsNovember 4, 2024
Cenobamate59285-064PowderBulk ingredientsAugust 23, 2024
Tapinarof (form-i)59285-066PowderBulk ingredientsApril 3, 2024
Dapagliflozin (anhydrous)59285-050PowderBulk ingredientsAugust 3, 2022
Dapagliflozin propanediol monohydrate59285-062PowderBulk ingredientsAugust 1, 2022
Brivaracetam59285-048PowderBulk ingredientsMarch 19, 2022
Midodrine hydrochloride59285-043PowderBulk ingredientsDecember 30, 2021
Linagliptin59285-047PowderBulk ingredientsDecember 20, 2021
Sitagliptin59285-042PowderBulk ingredientsAugust 23, 2021
Bempedoic acid59285-041PowderBulk ingredientsAugust 23, 2021
Molnupiravir59285-040PowderBulk ingredientsAugust 23, 2021
Dexlansoprazole59285-038PowderBulk ingredientsDecember 30, 2020
Dabigatran etexilate mesylate59285-036PowderBulk ingredientsDecember 30, 2020
Mesalamine59285-037PowderBulk ingredientsDecember 29, 2020
Zileuton59285-035PowderBulk ingredientsDecember 29, 2020
Linezolid59285-021PowderBulk ingredientsDecember 14, 2020
Cibenzoline succinate, (s)-59285-034PowderBulk ingredientsOctober 2, 2020
Chenodeoxycholic acid59285-033PowderBulk ingredientsJuly 22, 2020
Safinamide mesylate59285-031PowderBulk ingredientsJuly 20, 2020
Pregabalin59285-030PowderBulk ingredientsJuly 20, 2020
Obeticholic acid59285-028PowderBulk ingredientsDecember 26, 2019
Memantine hydrochloride59285-027PowderBulk ingredientsDecember 26, 2019
Trientine hydrochloride59285-026PowderBulk ingredientsDecember 26, 2019

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.